On Tuesday, 4D Molecular Therapeutics Inc (NASDAQ: FDMT) opened lower -5.14% from the last session, before settling in for the closing price of $11.08. Price fluctuations for FDMT have ranged from $2.23 to $12.34 over the past 52 weeks.
Healthcare Sector giant saw their annual sales slid by -9.89% over the last five years. Company’s average yearly earnings per share was noted -9.35% at the time writing. With a float of $50.88 million, this company’s outstanding shares have now reached $57.14 million.
4D Molecular Therapeutics Inc (FDMT) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of 4D Molecular Therapeutics Inc is 10.95%, while institutional ownership is 65.78%. The most recent insider transaction that took place on Nov 17 ’25, was worth 17,315. In this transaction Chief Legal Officer of this company sold 1,635 shares at a rate of $10.59, taking the stock ownership to the 3,594 shares. Before that another transaction happened on Nov 17 ’25, when Company’s Officer proposed sale 1,635 for $10.79, making the entire transaction worth $17,642.
4D Molecular Therapeutics Inc (FDMT) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.9 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.84) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.93 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.65% during the next five years compared to -9.89% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Check out the current performance indicators for 4D Molecular Therapeutics Inc (FDMT). In the past quarter, the stock posted a quick ratio of 8.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5004.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.94, a number that is poised to hit -0.53 in the next quarter and is forecasted to reach -3.48 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Analysing the last 5-days average volume posted by the [4D Molecular Therapeutics Inc, FDMT], we can find that recorded value of 0.73 million was lower than the volume posted last year of 0.85 million. As of the previous 9 days, the stock’s Stochastic %D was 42.81%.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 77.67%, which indicates a significant increase from 29.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.76 in the past 14 days, which was higher than the 0.67 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.42, while its 200-day Moving Average is $6.07. Now, the first resistance to watch is $10.96. This is followed by the second major resistance level at $11.42. The third major resistance level sits at $11.66. If the price goes on to break the first support level at $10.26, it is likely to go to the next support level at $10.02. Now, if the price goes above the second support level, the third support stands at $9.56.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
There are currently 57,135K shares outstanding in the company with a market cap of 600.49 million. Presently, the company’s annual sales total 40 K according to its annual income of -160,870 K. Last quarter, the company’s sales amounted to 90 K and its income totaled -56,880 K.
